Blueprint Medicines Archives -

News/ News/ News/ Oncology/ R&D

Blueprint cashes in on the past to build its future

Phil Taylor Ayvakit, Blueprint Medicines, financing, Gavreto, royalty pharma, sixth street 0 Comment

Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some

Blueprint cashes in on the past to build its future

https://pharmaphorum.com/news/blueprint-cashes-in-on-the-past-to-build-its-future/

News/ News/ Oncology

Blueprint inks deal to buy lung cancer biotech Lengo

Phil Taylor Blueprint Medicines, EGFR, Exkivity, Johnson & Johnson, Lengo Therapeutics, Non-small cell lung cancer, Oncology, Rybrevant, Takeda, Targeted Therapies 0 Comment

Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and

Blueprint inks deal to buy lung cancer biotech Lengo

https://pharmaphorum.com/news/blueprint-inks-deal-to-buy-lung-cancer-biotech-lengo/

Market Access/ News/ News

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer

Phil Taylor Blueprint Medicines, Eli Lilly, Gavreto, HEOR, NICE, Non-small cell lung cancer, RET inhibitor, Retsevmo, Roche 0 Comment

Eli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer

https://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/

News/ News/ Oncology

Roche, Blueprint’s RET cancer drug Gavreto cleared in EU

Phil Taylor Blueprint Medicines, Eli Lilly, EU, Gavreto, Oncology, regulatory approval, RET inhibitor, Retevmo, Roche 0 Comment

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers,

Roche, Blueprint’s RET cancer drug Gavreto cleared in EU

https://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/

Market Access/ News/ News

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

Phil Taylor Ayvakit, Blueprint Medicines, FDA approval, Novartis, Oncology, Rydapt, systemic mastocytosis 0 Comment

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM),

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

https://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/

News/ News/ Oncology

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Phil Taylor Blueprint Medicines, Gavreto, imaging, Oncology, Retevmo, Roche, thyroid cancer 0 Comment

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

https://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/

News/ News/ Oncology

Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drug

Richard Staines Blueprint Medicines, cancer, Eli Lilly, lung cancer, Roche 0 Comment

Cancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that

Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drug

https://pharmaphorum.com/news/blueprint-and-roche-take-on-lilly-as-fda-approves-ret-targeting-lung-cancer-drug/

News/ News/ Oncology

European regulators back Blueprint’s Ayvakyt for stomach tumours

Richard Staines Blueprint Medicines, cancer, GIST, stomach cancer 0 Comment

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain

European regulators back Blueprint’s Ayvakyt for stomach tumours

https://pharmaphorum.com/news/european-regulators-back-blueprints-ayvakyt-for-stomach-tumours/

News/ News/ Oncology

Roche signs $1.7bn deal with Blueprint around cancer drug pralsetinib

Richard Staines Blueprint Medicines, Eli Lilly, pralsetinib, Roche 0 Comment

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that

Roche signs $1.7bn deal with Blueprint around cancer drug pralsetinib

https://pharmaphorum.com/news/roche-signs-1-7bn-deal-with-blueprint-around-cancer-drug-pralsetinib/

Trending

Blueprint Medicines

Login